PGNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Progyny Inc (PGNY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, positive growth trends, and favorable analyst sentiment. While technical indicators are mixed, the overall outlook for the stock is positive, supported by strong demand, client retention, and new revenue opportunities.
The MACD is positive and expanding, indicating bullish momentum. RSI is in the neutral zone at 67.443, suggesting no overbought or oversold conditions. However, moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near key resistance levels (R1: 21.992, R2: 22.537). This indicates potential short-term resistance but does not negate the long-term growth potential.
Record revenue of $1.29 billion and adjusted EBITDA of $222 million for 2025, exceeding original guidance.
Nearly 100% client retention among large employers, with 30% expanding benefits for
Launch of Progyny Select to target 50 million smaller employers, expected to generate new revenue in
Analysts have raised price targets and upgraded ratings, citing strong demand, client retention, and new product potential.
Bearish moving averages indicate short-term resistance.
Broader market sentiment is slightly negative, with the S&P 500 down 0.36% in pre-market trading.
Progyny reported strong financial results for Q4 2025, with revenue increasing by 6.69% YoY, net income up 18.54% YoY, and EPS up 27.27% YoY. Gross margin also improved by 13.59%. The company exceeded EPS estimates consistently over the past two years and projects 2026 revenue growth between $1.355 billion and $1.405 billion, with adjusted EBITDA expected to range from $224 million to $239 million.
Analysts are highly optimistic about Progyny, with multiple upgrades and price target increases. BTIG raised its price target to $35, citing strong demand and favorable member engagement. Citizens upgraded the stock to Outperform, highlighting the company's moat and new solution potential. Truist and KeyBanc also raised price targets, emphasizing resilience in demand and conservative guidance.
